The remaining diabetic subjects were selected from the Young Diabetes in Oxford (YDX) study, comprising subjects diagnosed with diabetes ≤ 45 years of age recruited from either primary (n=84) or secondary (n=471) care. We included individuals with classical type 1 diabetes, (n=275), Latent Autoimmune Diabetes of Adulthood (LADA, n=41) and type 2 diabetes (n=240). Type 1 diabetes was defined as permanent insulin treatment since diagnosis with additional evidence of severe β-cell dysfunction (C-peptide ≤0.09nmol/l or HOMA %B < 10%), positive Glutamic acid decarboxylase antibodies (>14 WHO units/ml) or both. LADA was defined as diabetes diagnosed after 18 years of age with positive GAD antibodies where there had been no requirement for insulin treatment within 3 months of diagnosis. Diabetic subjects not requiring permanent insulin treatment at diagnosis and with negative GAD antibodies were classified as having type 2 diabetes. Subjects in this last category either did not meet clinical criteria for MODY diagnostic testing or had been tested and were negative for mutations in HNF1A, HNF4A (n=18) or GCK (n=7).
Non-diabetic subjects (n=198) were recruited from the Oxford Biobank (http://www.oxfordbrc.org/research/chronic-disease-cohorts/102/), a populationbased collection of healthy adults aged 30-50 recruited for translational medicine studies. One HNF1A-MODY subject, 5 type 1 diabetic subjects, 5 LADA subjects and 35 of the type 2 diabetic subjects were of non-European ethnicity (20 Asian, 18 Black, 1 Chinese, 7 mixed or other).
For all subjects, clinical details, anthropometry and blood samples were collected. The study was approved by the Oxfordshire Local Research Ethics Committee and all subjects gave informed consent.
Supplementary Figure 1:
Box plots of all hsCRP values. Box shows median and interquartile ranges, whiskers show adjacent values (the most extreme data points not considered outliers) and symbols are outliers. HsCRP levels are plotted on a log 10 scale.
Supplementary Table 1
Calculations of sensitivity and specificity for the listed criteria for identifying HNF1A-MODY cases from type 2 diabetes diagnosed ≤45 years based on our dataset. 
